Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial.
BioDrugs
; 37(1): 89-98, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-36417156
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biosimilar Pharmaceuticals
/
Ustekinumab
/
East Asian People
Type of study:
Clinical_trials
Limits:
Humans
/
Male
Language:
En
Journal:
BioDrugs
Journal subject:
ALERGIA E IMUNOLOGIA
/
GENETICA MEDICA
/
TERAPEUTICA
/
TERAPIA POR MEDICAMENTOS
Year:
2023
Type:
Article
Affiliation country:
China